NEWTOWN SQUARE, Pa., May 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating BioScrip, Inc. (“BioScrip” or the “Company”) (BIOS) on behalf of the Company’s shareholders.
On March 15, 2019, BioScrip announced that it had entered into an agreement to merge with Option Care Enterprises, Inc. (“Option Care”). According to the announcement, in connection with the proposed transaction BioScrip plans to issue over 542 million shares of common stock to Option Care’s shareholders, who are expected to own approximately 80% of the combined company upon completion of the transaction. Following this announcement, shares of BioScrip’s common stock declined over 20% in value.
The investigation seeks to determine whether BioScrip’s executive officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the proposed transaction, and whether BioScrip shareholders are receiving all material information in connection with the transaction.
BioScrip shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740, or via http://kaskelalaw.com/case/bioscrip/, to discuss this investigation and their legal rights and options with respect to this transaction.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
This notice may constitute attorney advertising in certain jurisdictions.